BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodriguez-Osorio L, Ortiz A. Timing of eculizumab therapy for C3 glomerulonephritis. Clin Kidney J. 2015;8:449-452. [PMID: 26251715 DOI: 10.1093/ckj/sfv065] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Yeter HH, Sütiçen E, Korucu B, Helvaci Ö, Özbaş B, Gönül İ, Derici Ü, Arinsoy T, Güz G. Evaluation of Clinical, Laboratory and Treatment Modalities in C3 Glomerulopathy: Single Center Experience. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2019;40:15-23. [PMID: 31605593 DOI: 10.2478/prilozi-2019-0010] [Reference Citation Analysis]
2 Zilberman-Itskovich S, Abu-Hamad R, Stark M, Efrati S. Effect of anti-C5 antibody on recuperation from ischemia/reperfusion-induced acute kidney injury. Ren Fail 2019;41:967-75. [PMID: 31662004 DOI: 10.1080/0886022X.2019.1677248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Abbas F, El Kossi M, Jin JK, Sharma A, Halawa A. De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases? World J Transplant 2017; 7(6): 285-300 [PMID: 29312858 DOI: 10.5500/wjt.v7.i6.285] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand: Thrombotic microangiopathy in Aust/NZ. Nephrology 2018;23:507-17. [DOI: 10.1111/nep.13234] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
5 Perez-Gomez MV, Ortiz A. Aliskiren and the dual complement inhibition concept. Clin Kidney J 2020;13:35-8. [PMID: 32083617 DOI: 10.1093/ckj/sfz142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy. Diagn Pathol. 2016;11:94. [PMID: 27717365 DOI: 10.1186/s13000-016-0547-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Lioufas N, Finlay M, Barbour T. Durable remission of C3 glomerulonephritis with mycophenolate mofetil. Nephrology (Carlton) 2017;22 Suppl 1:36-9. [PMID: 28176473 DOI: 10.1111/nep.12939] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrología (English Edition) 2017;37:478-91. [DOI: 10.1016/j.nefroe.2017.08.001] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 Sanchez-Niño MD, Ortiz A. Thrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advances. Clin Kidney J 2015;8:686-9. [PMID: 26613024 DOI: 10.1093/ckj/sfv115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
10 Keir LS, Langman CB. Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis. Transfus Apher Sci 2016;54:203-11. [PMID: 27156109 DOI: 10.1016/j.transci.2016.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
11 Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand: Thrombotic microangiopathy in Australia/New Zealand. Intern Med J 2018;48:624-36. [DOI: 10.1111/imj.13804] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
12 Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrologia 2017;37:478-91. [PMID: 28946961 DOI: 10.1016/j.nefro.2017.01.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
13 Spartà G, Gaspert A, Neuhaus TJ, Weitz M, Mohebbi N, Odermatt U, Zipfel PF, Bergmann C, Laube GF. Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series. Clin Kidney J 2018;11:479-90. [PMID: 30094012 DOI: 10.1093/ckj/sfy006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]